MRNA - Moderna, Inc. Stock Analysis

Latest News

SEEKING ALPHA · OCT 8, 2026

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Imdusiran, ABUS's RNAi asset for chronic hepatitis B, targets a functional cure and could generate $1.59–$2.39B in peak annual revenue if successful. Current valuation ($4.50/share) slightly exceeds risk-adjusted fair value ($3.91), with upside tied to positive Phase 2b/3 Imdusiran results.

READ ARTICLE

EARLIER COVERAGE

ZACKS INVESTMENT RESEARCH · OCT 8, 2026

Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?

MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.

READ ARTICLE

247 WALLST · OCT 8, 2026

3 Stocks That Have More Than Doubled the S&P 500’s Return This Year

Three stocks left the S&P 500's 2025 return in the dust, but gains that large raise one uncomfortable question: is the opportunity already gone, or does one of them still have a real runway ahead?

READ ARTICLE

THE MOTLEY FOOL · OCT 7, 2026

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market. Moderna is moving beyond its pandemic roots by advancing a deep pipeline of mRNA-based vaccines and oncology therapies.

READ ARTICLE

INVESTOPEDIA · OCT 7, 2026

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

The healthcare sector stood out as one of the few bright spots in Wednesday's trading.

READ ARTICLE

SEEKING ALPHA · OCT 7, 2026

Cedar Grove Capital Q3 2026 Portfolio Update

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.

READ ARTICLE

BENZINGA · OCT 7, 2026

Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure

Tempus Inc. (NASDAQ:TEM) on Wednesday expanded its multi-year collaboration for intismeran autogene (V940/mRNA-4157) individualized neoantigen therapy (INT) combined with Keytruda (pembrolizumab) for completely resected stage IIB-IV melanoma and other cancer types.

READ ARTICLE

BUSINESS WIRE · OCT 7, 2026

Tempus Announces Multi-Year Collaboration with Moderna and Merck

CHICAGO--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know.

READ ARTICLE

FOOL - INVESTING NEWS · OCT 6, 2026

Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026?

These stocks have all soared more than 350% this year.

READ ARTICLE

24/7 WALL STREET · OCT 6, 2026

Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run now raises a hard question about what comes next. Moderna stock is up 545% year-to-date to $190.

READ ARTICLE

SHOWING 2–10 OF 26